Abstract
In this paper, we measure the extent to which a biological marker is a surrogate endpoint for a clinical event by the proportional reduction in the regression coefficient for the treatment indicator due to the inclusion of the marker in the Cox regression model. We estimate this proportion by applying the partial likelihood function to two Cox models postulated on the same failure time variable. We show that the resultant estimator is asymptotically normal with a simple variance estimator. One can construct confidence intervals for the proportion by using the direct normal approximation to the point estimator or by using Fieller's theorem. Extensive simulation studies demonstrate that the proposed methods are appropriate for practical use. We provide applications to HIV/AIDS clinical trials.
Keywords
EstimatorStatisticsSurrogate endpointConfidence intervalProportional hazards modelMathematicsRegression analysisPoint estimationLinear regressionRegressionEconometricsApplied mathematicsMedicineInternal medicine
Affiliated Institutions
Related Publications
Meta-analysis for the evaluation of potential surrogate markers
We describe a meta-analysis approach for the evaluation of a potential surrogate marker. Surrogate markers are useful in helping to identify therapeutic mechanisms of action and...
Surrogate Markers in AIDS: Where Are We? Where Are We Going?
Editorials1 April 1992Surrogate Markers in AIDS: Where Are We? Where Are We Going?Stephen W. Lagakos, PhD, Daniel F. Hoth, MDStephen W. Lagakos, PhD, Daniel F. Hoth, MDAuthor, A...
Regression Analysis of Multivariate Incomplete Failure Time Data by Modeling Marginal Distributions
Abstract Many survival studies record the times to two or more distinct failures on each subject. The failures may be events of different natures or may be repetitions of the sa...
Surrogate End Points in Clinical Trials: Are We Being Misled?
Phase 3 clinical trials, which evaluate the effect that new interventions have on the clinical outcomes of particular relevance to the patient (such as death, loss of vision, or...
Importance of Surrogate Markers in Evaluation of Antiviral Therapy for HIV Infection
CONVENTIONAL randomized clinical trials of new treatments usually rely on clinical end points that directly show the effect of the new treatment on outcomes such as quality or l...
Publication Info
- Year
- 1997
- Type
- article
- Volume
- 16
- Issue
- 13
- Pages
- 1515-1527
- Citations
- 496
- Access
- Closed
External Links
Social Impact
Altmetric
PlumX Metrics
Social media, news, blog, policy document mentions
Citation Metrics
496
OpenAlex
Cite This
D. Y. Lin,
Thomas R. Fleming,
Victor De Gruttola
(1997).
ESTIMATING THE PROPORTION OF TREATMENT EFFECT EXPLAINED BY A SURROGATE MARKER.
Statistics in Medicine
, 16
(13)
, 1515-1527.
https://doi.org/10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1
Identifiers
- DOI
- 10.1002/(sici)1097-0258(19970715)16:13<1515::aid-sim572>3.0.co;2-1